PHVS: Pharvaris NV Company Value to Net Income
Pharvaris N.V. (PHVS) develops oral treatments for hereditary angioedema with a valuable pipeline. The company's P/E ratio objectively reflects the asset's investment attractiveness, with the indicator currently standing at -11.90. The transition to tablet forms simplifies logistics and scales the customer base. However, high R&D costs coupled with a revenue deficit are leading to the depletion of reserves and a search for external capital.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_PHVS_-_Pharvaris-N.V._-_PE-Multiple "PHVS: Pharvaris N.V. Business Payback Period 07/04/2022 - 11/15/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Pharvaris Pharma (PHVS)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
PHVS - Net Profit|Expected Net Income Pharvaris N.V.|PHVS - P/E Multiple|Forward P/E Multiple Pharvaris Pharma|PHVS - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Pharvaris Pharma|PHVS - Operating profit before deduction of amortization|Earnings per share for the last twelve months Pharvaris|PHVS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth pharvaris.com|PHVS - Earnings per share growth in current year|Expected earnings per share trend next year Pharvaris N.V.
- sales volume and revenue indicators:
Comprehensive company analysis:Pharvaris PHVS
The transparency of clinical roadmaps and the high scientific expertise of Pharvaris N.V. management allow investors to assess the value of each unit of profit via the company's current P/E on the GURU.Markets platform. The value of -11.90 reflects market expectations for the business capitalization, where low multiples may signal either undervaluation or systemic risks within the biotechnology sector.
Key competitors
P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Price to Earnings Ratio|Grifols Biemat (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotechnologies|Price to Earnings Ratio CLDX|P/E Multiple auriniapharma.com|Price to Earnings Ratio BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Earnings Multiple|P/E Multiple DNTH (dianthustx.com)|AbCellera Bio (ABCL) - Market Cap to Earnings|TRML: Price to Earnings Ratio|Market Cap to Net Income PGEN|PHAR: P/E Multiple|Market Cap to Earnings Nektar Therapeutics Inc (NKTR)|Price to Earnings Ratio UPB|Price to Earnings Multiple ZBIO (Zenas Biopharma, Inc.)|Price to Earnings Ratio IMNM (Immunome Bio)|Business Payback Period Gossamer Bio, Inc.|P/E Multiple KALV (KalVista Pharma)|Septerna, Inc. (SEPN) - Market Cap to Earnings|PVLA - Price to Earnings Ratio|SVRA - P/E Multiple|Rigel Pharmaceuticals Inc (RIGL) - Price to Earnings Ratio|ANAB - Business Payback Period|Price to Earnings Ratio ATXS|ENGN: Company Value to Net Income|Price to Earnings Ratio RAPT Therapeutics (RAPT)|JBIO (Aerovate) - Company Value to Net Income|P/E Multiple ACRS (Aclaris Therapeutics)|Company Value to Net Income KYTX|Tiziana Life Sciences - P/E Multiple|CABA: Price to Earnings Ratio|VTYX: P/E Multiple|THTX (Theratechnologies, Inc) - Price to Earnings Ratio|AVTX (Avalo Therapeutics, Inc.) - P/E Multiple|P/E Multiple Eledon Pharmaceuticals|Price to Earnings Ratio Agenus Inc. (AGEN)|Price to Earnings Ratio Climb Bio Inc. CLYM|P/E Multiple ZURA (Zura Bio Ltd)|ATYR - Price to Earnings Ratio|ADAG - Price to Earnings Ratio|IMA - P/E Multiple|STTK: P/E Multiple|Equillium Bio (EQ) - P/E Multiple|CNTB (connectbiopharm.com) - P/E Multiple|IMUX: Company Value to Net Income|P/E Multiple ATRA|P/E Multiple InflaRx NV (IFRX)|X4 Pharmaceuticals, Inc. (XFOR) - Market Cap to Net Income|P/E Multiple adicetbio.com ACET|Celularity - P/E Multiple|Company Value to Net Income INMB (INmune Bio Corp)|BRNS (Barinthus Bio) - Price to Earnings Ratio|Market Cap to Net Income KZR (Kezar Life Sciences)|Price to Earnings Ratio SAB Biotherapeutics Inc.|Akari Therapeutics Plc - Market Cap to Net Income|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd.)|Price to Earnings Ratio Q32 Bio Inc QTTB|Price to Earnings Ratio geovax.com GOVX|P/E Multiple edesabiotech.com EDSA|iBio Corporation - P/E Multiple|Company Value to Net Income CARM (carismatx.com)|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Bolt Bio (BOLT) - P/E Multiple|HCWB (HCW Biologics Inc) - P/E Multiple|Price to Earnings Ratio Aptevo Therapeutics (APVO)|P/E Multiple AIM|Market Price to Net Income Ratio ADTX|P/E Multiple GRI (GRI Bio Corporation)|P/E Multiple XORTX Corp XRTX|HIND - Price to Earnings Ratio|Revelation Biosciences (REVB) - Price to Earnings Ratio|INDP (Indaptus Therapeutics, Inc.) - Price to Earnings Ratio|Scinai Immunotherapeutics Ltd (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|affimed.com - Market Cap to Net Income|Price to Earnings Ratio allakos.com (ALLK)|P/E Multiple HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Price to Earnings Ratio|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple
